Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah C Gilbert

Showing results (151-160 of 215) with videos related to

Pageof 22
Sort By:
Scientific Reports|April 24, 2013
The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessmentAnna L Goodman, Emily K Forbes, Andrew R Williams, et al.
Med (New York, N.Y.)|February 1, 2021
A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged miceAlyssa Silva-Cayetano, William S Foster, Silvia Innocentin, et al.
Biotechnology and Bioengineering|July 13, 2022
Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditionsEkta Mukhopadhyay, Florian Brod, Philip Angell-Manning, et al.
Plos One|April 16, 2009
MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaquesFrank A W Verreck, Richard A W Vervenne, Ivanela Kondova, et al.
Nature Medicine|September 30, 2021
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infectionShuo Feng, Daniel J Phillips, Thomas White, et al.
Human Vaccines & Immunotherapeutics|November 13, 2012
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trialRosalind Rowland, Ansar A Pathan, Iman Satti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2012
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humansPatrick J Lillie, Tamara K Berthoud, Timothy J Powell, et al.
Nature Communications|October 8, 2021
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7Robert J Fischer, Neeltje van Doremalen, Danielle R Adney, et al.
ACS Central Science|May 31, 2021
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 VaccineYasunori Watanabe, Luiza Mendonça, Elizabeth R Allen, et al.
Scientific Reports|February 23, 2018
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAPCarly M Bliss, Georgina Bowyer, Nicholas A Anagnostou, et al.
Pageof 22

Showing results (151-160 of 215) with videos related to

Sort By:
Pageof 22
Scientific Reports|April 24, 2013
The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessmentAnna L Goodman, Emily K Forbes, Andrew R Williams, et al.
Med (New York, N.Y.)|February 1, 2021
A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged miceAlyssa Silva-Cayetano, William S Foster, Silvia Innocentin, et al.
Biotechnology and Bioengineering|July 13, 2022
Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditionsEkta Mukhopadhyay, Florian Brod, Philip Angell-Manning, et al.
Plos One|April 16, 2009
MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaquesFrank A W Verreck, Richard A W Vervenne, Ivanela Kondova, et al.
Nature Medicine|September 30, 2021
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infectionShuo Feng, Daniel J Phillips, Thomas White, et al.
Human Vaccines & Immunotherapeutics|November 13, 2012
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trialRosalind Rowland, Ansar A Pathan, Iman Satti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2012
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humansPatrick J Lillie, Tamara K Berthoud, Timothy J Powell, et al.
Nature Communications|October 8, 2021
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7Robert J Fischer, Neeltje van Doremalen, Danielle R Adney, et al.
ACS Central Science|May 31, 2021
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 VaccineYasunori Watanabe, Luiza Mendonça, Elizabeth R Allen, et al.
Scientific Reports|February 23, 2018
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAPCarly M Bliss, Georgina Bowyer, Nicholas A Anagnostou, et al.
Pageof 22